Skip to main content

Table 6 Change in physician global assessment of disease activity, all dose groups combined

From: Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds

  Categories of change in physician global assessment of disease activity
  > +10 (n = 8) +10 to -10 (n = 44) -11 to -20 (n = 33) -21 to -40 (n = 56) < -40 (n = 43) F p-value
PRO Instruments        
SF-36        
Physical functioning -5.6 (27.9) 1.6 (13.2) 2.7 (12.6) 10.1 (19.5) 14.3 (19.7) 4.8 0.0010
Role physical -8.9 (13.0) 1.8 (17.7) 6.3 (19.4) 11.2 (21.2) 21.0 (25.9) 6.4 0.0001
Bodily pain -6.6 (13.4) -0.8 (15.7) 6.4 (18.8) 14.3 (14.2) 22.2 (22.3) 12.3 0.0000
General health -5.9 (17.2) -1.2 (14.7) 4.2 (12.4) 3.6 (14.6) 8.5 (13.3) 3.4 0.0097
Vitality 0.0 (13.8) -3.1 (18.5) 1.9 (19.7) 7.4 (13.8) 20.7 (22.1) 10.3 0.0000
Social functioning -15.6 (23.8) -3.1 (24.1) 0.0 (22.9) 8.7 (19.9) 16.7 (30.9) 5.7 0.0003
Role emotional -10.4 (25.5) -3.4 (23.7) 1.9 (22.9) 7.7 (24.6) 13.3 (28.9) 3.4 0.0109
Mental health -8.1 (13.1) -4.0 (15.4) 5.0 (16.2) 4.0 (16.7) 14.5 (19.7) 7.6 0.0000
Physical summary -1.8 (8.0) 1.0 (4.9) 1.9 (4.9) 4.5 (5.9) 6.5 (7.8) 6.7 0.0000
Mental summary -4.8 (10.5) -.27 (9.2) 1.1 (8.9) 2.4 (8.6) 7.5 (12.8) 6.5 0.0001
HAQ-DI 0.03 (0.44) 0.05 (0.33) -0.14 (0.36) -0.28 (0.41) -0.54 (0.53) 9.1 0.0000
FACIT-Fatigue -4.7 (5.5) -0.6 (7.8) 2.5 (7.1) 4.1 (6.2) 9.6 (7.2) 14.8 0.0000